Under the agreement, Aspen will have exclusive rights to launch and commercialize selected products from Viramal’s portfolio in Europe, the Middle East, Brazil and Mexico.
Daniel Vella Friggieri, Regional CEO – Aspen Europe & Middle East, said, “This agreement underscores Aspen’s continued commitment to advancing innovation across Europe and the Middle East. We are proud to partner with Viramal to further strengthen our Women’s Health portfolio by providing women with access to a broader range of therapies, including enhanced formulations designed to address significant unmet needs.”
Oliver Bates, CEO of Viramal, commented, “We are delighted to partner with Aspen, whose commitment to innovation in Women’s Health aligns perfectly with our mission. The collaboration leverages Viramal’s Fem Med Tech™ platform, a proprietary and patent-protected suite of formulation and drug delivery technologies targeting unmet needs in Women’s Health.
Read the full announcement here:
www.aspenpharmaeme.com/news/aspen-concludes-an-exclusive-womens-health-portfolio-licensing-agreement-with-viramal
